On Nov 05, major Wall Street analysts update their ratings for $Editas Medicine (EDIT.US)$, with price targets ranging from $5 to $12.
Barclays analyst Gena Wang maintains with a hold rating, and adjusts the target price from $7 to $5.
Wells Fargo analyst Yanan Zhu maintains with a buy rating, and adjusts the target price from $9 to $7.
TD Cowen analyst Phil Nadeau maintains with a buy rating.
RBC Capital analyst Luca Issi maintains with a hold rating, and adjusts the target price from $8 to $5.
Raymond James analyst Steven Seedhouse downgrades to a hold rating.
Furthermore, according to the comprehensive report, the opinions of $Editas Medicine (EDIT.US)$'s main analysts recently are as follows:
The recent quarterly update from Editas Medicine was seen as incremental after the company's strategic revision, an analyst noted to investors.
The emphasis by Editas Medicine on in vivo HSPC editing is viewed by analysts as a strategic utilization of its expertise and resources to generate value. Anticipation is building for the forthcoming in vivo pipeline update slated for the first quarter of 2025, alongside developments on reni-cel BD activity.
The recent quarter is viewed as incremental following the strategic shift that was recently announced. Editas Medicine has shifted its focus towards partnering or out-licensing its leading asset for SCD/BT, centering attention on the in vivo pipeline. This move is deemed a sound strategy given the gradual adoption observed thus far for the class. Nevertheless, a position of watchfulness is maintained, pending additional advancements in the in vivo pipeline.
Here are the latest investment ratings and price targets for $Editas Medicine (EDIT.US)$ from 6 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美東時間11月5日，多家華爾街大行更新了$Editas Medicine (EDIT.US)$的評級，目標價介於5美元至12美元。
巴克萊銀行分析師Gena Wang維持持有評級，並將目標價從7美元下調至5美元。
富國集團分析師Yanan Zhu維持買入評級，並將目標價從9美元下調至7美元。
TD Cowen分析師Phil Nadeau維持買入評級。
加皇資本市場分析師Luca Issi維持持有評級，並將目標價從8美元下調至5美元。
瑞傑金融分析師Steven Seedhouse下調至持有評級。
此外，綜合報道，$Editas Medicine (EDIT.US)$近期主要分析師觀點如下：
分析師指出，editas medicine最近的季度更新在公司戰略修訂之後被視爲漸進性的。
分析師認爲，editas medicine強調體內HSPC基因編輯被視爲對其專業知識和資源的戰略利用，以創造價值。人們對於計劃在2025年第一季度公佈的體內管線更新以及reni-cel BD活動的進展充滿期待。
最近的季度被視爲在最近宣佈的戰略轉變之後的漸進性。editas medicine已將焦點轉向與SCD/Bt領先資產合作伙伴或外部許可，並將注意力集中在體內管線上。鑑於迄今爲止對該類別的漸進採納，此舉被視爲一項明智策略。儘管如此，對於體內管線的進一步發展仍保持警惕態度。
以下爲今日6位分析師對$Editas Medicine (EDIT.US)$的最新投資評級及目標價：
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
